Literature DB >> 16675565

Thymidylate synthase expression in colon carcinomas with microsatellite instability.

Frank A Sinicrope1, Rafaela L Rego, Kevin C Halling, Nathan R Foster, Daniel J Sargent, Betsy La Plant, Amy J French, Carmen J Allegra, John A Laurie, Richard M Goldberg, Thomas E Witzig, Stephen N Thibodeau.   

Abstract

PURPOSE: Colon cancer cells with high-frequency microsatellite instability (MSI-H) display resistance to 5-fluorouracil (5-FU) that can be reversed by restoring DNA mismatch repair (MMR) proficiency. Given that thymidylate synthase (TS) is inhibited by 5-FU, we studied the relationship between MSI and TS expression, and the prognostic effect of these and other markers (i.e., p53 and 17p allelic imbalance). EXPERIMENTAL
DESIGN: Dukes' stage B2 and C colon carcinomas (n = 320) from participants in 5-FU-based adjuvant therapy trials were analyzed for MSI and 17p allelic imbalance. Expression of MMR (hMLH1, hMSH2), TS, and p53 proteins were analyzed by immunohistochemistry. Correlations between markers and associations with overall survival were determined.
RESULTS: Of 320 cancers studied, 60 (19%) were MSI-H. TS expression variables were similar in MSI-H and microsatellite stable/low-frequency MSI (MSS/MSI-L) cancers, and unrelated to MMR proteins. MSI-H tumors had lower stage (P = 0.0007), fewer metastatic lymph nodes (P = 0.004), and improved overall survival (P = 0.01). Loss of MMR proteins was also associated with better overall survival (P = 0.006). None of the TS variables were prognostic. Histologic grade (P = 0.0008) and nodal status (P = 0.0002) were associated with overall survival, in contrast to 17p allelic imbalance or p53. Only MSI status or loss of MMR proteins, histologic grade, and tumor stage were independent markers for overall survival.
CONCLUSIONS: MSI-H tumors show earlier stage at presentation and better stage-adjusted survival rates. MSI status and TS expression were unrelated and TS was not prognostic, suggesting that TS levels cannot explain therapeutic resistance to 5-FU reported in MSI-H colon cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675565     DOI: 10.1158/1078-0432.CCR-06-0178

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers.

Authors:  Frank A Sinicrope; Rafaela L Rego; Nathan R Foster; Stephen N Thibodeau; Steven R Alberts; Harold E Windschitl; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.

Authors:  Marisa Donada; Serena Bonin; Ermanno Nardon; Alessandro De Pellegrin; Giuliana Decorti; Giorgio Stanta
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-13       Impact factor: 4.553

3.  Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.

Authors:  Heyu Song; Jiping Zeng; Shrabasti Roychoudhury; Pranjal Biswas; Bhopal Mohapatra; Sutapa Ray; Kayvon Dowlatshahi; Jing Wang; Vimla Band; Geoffrey Talmon; Kishor K Bhakat
Journal:  Mol Cancer Ther       Date:  2019-10-01       Impact factor: 6.261

4.  Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.

Authors:  Frank A Sinicrope; Zhineng Jayson Yang
Journal:  Future Oncol       Date:  2011-03       Impact factor: 3.404

5.  Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.

Authors:  Frank Sinicrope; Nathan R Foster; Daniel J Sargent; Stephen N Thibodeau; Thomas C Smyrk; Michael J O'Connell
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

Review 6.  Clinical implications of microsatellite instability in sporadic colon cancers.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Curr Opin Oncol       Date:  2009-07       Impact factor: 3.645

7.  Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Ewa Majdanik; Maria Chosia; Dariusz Bielicki; Jozef Kladny; Mariusz Kaczmarczyk; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2009-05-15       Impact factor: 4.064

8.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.

Authors:  R L Rego; N R Foster; T C Smyrk; M Le; M J O'Connell; D J Sargent; H Windschitl; F A Sinicrope
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

9.  Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.

Authors:  Mads Aarhus; Ove Bruland; Geir Bredholt; Helle Lybaek; Eystein S Husebye; Bård K Krossnes; Christian Vedeler; Knut Wester; Morten Lund-Johansen; Per M Knappskog
Journal:  J Neurooncol       Date:  2008-03-26       Impact factor: 4.130

Review 10.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.